Lestaurtinib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lestaurtinib
Lestaurtinib.png
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
PubChem CID 126565
UNII DO989GC5D1 N
KEGG D04696 YesY
ChEMBL CHEMBL603469 N
Chemical data
Formula C26H21N3O4 
Mol. mass 439.462 g/mol
 N (what is this?)  (verify)

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine, and is being developed by Cephalon.

It is an inhibitor of FLT3,[1] JAK2,[2] TrkA, TrkB and TrkC.[3]

Uses[edit]

It is undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders.

As of 2009, it is in Phase II clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.[4][5]

See also[edit]

References[edit]